← Back to Search

Other

Dexamethasone + Azeliragon for Brain Swelling After Glioblastoma Surgery

Phase 1
Waitlist Available
Led By Jana L Portnow
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Karnofsky performance status of >= 60%
Histologically confirmed glioblastoma or radiographic findings consistent with a high grade glioma in patients undergoing surgery for initial diagnosis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 30 days post-last dose of protocol therapy
Awards & highlights

Study Summary

This trial tests the safety & side effects of giving dexamethasone & azeliragon to help reduce brain swelling after surgery for glioblastoma.

Who is the study for?
Adults with confirmed glioblastoma or signs of high-grade glioma who are undergoing surgery can join. They must have a good performance status, not be in another trial, and have recovered from previous treatments. Women of childbearing age need a negative pregnancy test and agree to birth control. Participants should not have severe illnesses, bleeding disorders, HIV, other cancers, or be unable to take oral meds or undergo MRIs.Check my eligibility
What is being tested?
The trial is testing the safety and optimal dose of dexamethasone combined with azeliragon for reducing brain swelling after tumor removal surgery in glioblastoma patients. Dexamethasone is an anti-inflammatory steroid; azeliragon blocks RAGE pathways potentially decreasing cerebral edema.See study design
What are the potential side effects?
Possible side effects include immune system suppression leading to increased infection risk, blood sugar increases (common with steroids like dexamethasone), potential digestive issues due to oral medication intake (azeliragon), mood swings or sleep disturbances from steroids.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You are able to perform daily tasks and activities without much difficulty.
Select...
You have been diagnosed with a specific type of brain tumor called glioblastoma, or your brain scan shows signs of a high-grade glioma, and you are about to have surgery to confirm the diagnosis.
Select...
You are planning to have a standard surgery to remove a brain tumor, and the doctor thinks they can remove the entire tumor.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 30 days post-last dose of protocol therapy
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 30 days post-last dose of protocol therapy for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of adverse events
Lack of feasibility
Secondary outcome measures
Azeliragon concentrations
Cytokines/chemokines
Volume of cerebral edema

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm I (azeliragon, dexamethasone)Experimental Treatment5 Interventions
Patients receive azeliragon PO and dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
Group II: Arm II (dexamethasone)Active Control4 Interventions
Patients receive dexamethasone PO or IV throughout the study. Patients also undergo collection of cavity fluid and blood samples, CT scan, and brain MRI with or without contrast throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexamethasone
2007
Completed Phase 4
~2590
Biospecimen Collection
2004
Completed Phase 2
~1730
Computed Tomography
2017
Completed Phase 2
~2720

Find a Location

Who is running the clinical trial?

City of Hope Medical CenterLead Sponsor
565 Previous Clinical Trials
1,921,439 Total Patients Enrolled
12 Trials studying Glioblastoma
335 Patients Enrolled for Glioblastoma
National Cancer Institute (NCI)NIH
13,654 Previous Clinical Trials
40,933,132 Total Patients Enrolled
322 Trials studying Glioblastoma
23,094 Patients Enrolled for Glioblastoma
Jana L PortnowPrincipal InvestigatorCity of Hope Medical Center
4 Previous Clinical Trials
117 Total Patients Enrolled
2 Trials studying Glioblastoma
54 Patients Enrolled for Glioblastoma

Media Library

Azeliragon (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05773664 — Phase 1
Glioblastoma Research Study Groups: Arm II (dexamethasone), Arm I (azeliragon, dexamethasone)
Glioblastoma Clinical Trial 2023: Azeliragon Highlights & Side Effects. Trial Name: NCT05773664 — Phase 1
Azeliragon (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05773664 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there any risk of harm associated with the combination of azeliragon and dexamethasone?

"With the limited data available to our team at Power, we assessed arm I (azeliragon and dexamethasone) with a score of 1 on safety. This is due to its Phase 1 clinical trial status, indicating that there has been little evidence towards both efficacy and safety thus far."

Answered by AI

Are new participants being taken into this clinical trial at the moment?

"According to the information disseminated on clinicaltrials.gov, this study is currently not enrolling any individuals. This trial was initially posted in June of 2023 and last modified in March of the same year. Although no longer recruiting participants, 729 other medical trials are actively seeking candidates at present."

Answered by AI
~14 spots leftby Nov 2024